BioAtla (BCAB) EBT Margin (2020 - 2026)

BioAtla (BCAB) posted quarterly EBT Margin of 459.1% for Q4 2025, down 326.24% quarter-over-quarter from 107.71% in Q3 2024.

BioAtla (BCAB) EBT Margin (2020 - 2026) Analysis & Trends

BioAtla's EBT Margin history runs 4 years deep, the most recent figure standing at 459.1% for Q4 2025.

In Q4 2025, EBT Margin changed N/A year-over-year to 459.1%; the TTM figure through Dec 2025 stood at 524.88% (up 423133.0% YoY), while the FY2025 annual figure was 8719.7%, down 714489.0% from the prior year.
EBT Margin for Q4 2025 stood at 459.1%, down from 107.71% in the prior quarter.
The five-year high for EBT Margin was 107.71% in Q3 2024, with the low at 18231.6% in Q2 2021.
The 3-year median for EBT Margin is 459.1% (2025), against an average of 6266.14%.
Peak annual rise in EBT Margin reached 1545634 bps in 2021, while the deepest fall reached 1545634 bps in 2021.
BioAtla's EBT Margin stood at 18231.6% in 2021, then surged by 99 bps to 107.71% in 2024, then slumped by 326 bps to 459.1% in 2025.
Business Quant data shows BCAB's EBT Margin at 459.1% in Q4 2025, 107.71% in Q3 2024, and 18231.6% in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	BioAtla	5.28 Mn	5.28 Mn	-	3.57%

Download Data